Ayala Pharmaceuticals (NASDAQ:AYLA) issued its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04), Fidelity Earnings reports.
Ayala Pharmaceuticals stock opened at $10.28 on Friday. Ayala Pharmaceuticals has a one year low of $8.62 and a one year high of $16.50. The stock’s fifty day simple moving average is $12.00.
A number of equities research analysts have weighed in on the company. Oppenheimer restated a “buy” rating and issued a $23.00 target price on shares of Ayala Pharmaceuticals in a research report on Thursday, August 13th. Raymond James restated a “buy” rating on shares of Ayala Pharmaceuticals in a research report on Thursday, August 13th. Finally, Zacks Investment Research upgraded Ayala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.00.
Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.